Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Chemoenzymatic Approaches to the Synthesis of the Calcimimetic Agent Cinacalcet Employing Transaminases and Ketoreductases.

Marx L, Ríos-Lombardía N, Farnberger JF, Kroutil W, Benítez-Mateos AI, López-Gallego F, Morís F, González-Sabín J, Berglund P.

Adv Synth Catal. 2018 Jun 5;360(11):2157-2165. doi: 10.1002/adsc.201701485. Epub 2018 Feb 28.

2.

New Insights into the Biosynthesis Pathway of Polyketide Alkaloid Argimycins P in Streptomyces argillaceus.

Ye S, Braña AF, González-Sabín J, Morís F, Olano C, Salas JA, Méndez C.

Front Microbiol. 2018 Feb 16;9:252. doi: 10.3389/fmicb.2018.00252. eCollection 2018.

3.

Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.

Puente-Moncada N, Costales P, Antolín I, Núñez LE, Oro P, Hermosilla MA, Pérez-Escuredo J, Ríos-Lombardía N, Sanchez-Sanchez AM, Luño E, Rodríguez C, Martín V, Morís F.

Mol Cancer Ther. 2018 Mar;17(3):614-624. doi: 10.1158/1535-7163.MCT-17-0530. Epub 2018 Jan 16.

PMID:
29339551
4.

Correction to: Increased heterologous production of the antitumoral polyketide mithramycin a by engineered Streptomyces lividans TK24 strains.

Novakova R, Núñez LE, Homerova D, Knirschova R, Feckova L, Rezuchova B, Sevcikova B, Menéndez N, Morís F, Cortés J, Kormanec J.

Appl Microbiol Biotechnol. 2018 Jan;102(2):871. doi: 10.1007/s00253-017-8710-x.

PMID:
29279959
5.

Increased heterologous production of the antitumoral polyketide mithramycin A by engineered Streptomyces lividans TK24 strains.

Novakova R, Núñez LE, Homerova D, Knirschova R, Feckova L, Rezuchova B, Sevcikova B, Menéndez N, Morís F, Cortés J, Kormanec J.

Appl Microbiol Biotechnol. 2018 Jan;102(2):857-869. doi: 10.1007/s00253-017-8642-5. Epub 2017 Dec 1. Erratum in: Appl Microbiol Biotechnol. 2017 Dec 27;:.

PMID:
29196786
6.

Asymmetric Reduction of Prochiral Ketones by Using Self-Sufficient Heterogeneous Biocatalysts Based on NADPH-Dependent Ketoreductases.

Benítez-Mateos AI, San Sebastian E, Ríos-Lombardía N, Morís F, González-Sabín J, López-Gallego F.

Chemistry. 2017 Nov 27;23(66):16843-16852. doi: 10.1002/chem.201703475. Epub 2017 Nov 8.

PMID:
28940802
7.

Identification by Genome Mining of a Type I Polyketide Gene Cluster from Streptomyces argillaceus Involved in the Biosynthesis of Pyridine and Piperidine Alkaloids Argimycins P.

Ye S, Molloy B, Braña AF, Zabala D, Olano C, Cortés J, Morís F, Salas JA, Méndez C.

Front Microbiol. 2017 Feb 10;8:194. doi: 10.3389/fmicb.2017.00194. eCollection 2017.

8.

High-Quality Draft Genome Sequence of the Actinobacterium Nocardia terpenica IFM 0406, Producer of the Immunosuppressant Brasilicardins, Using Illumina and PacBio Technologies.

Buchmann A, Eitel M, Koch P, Schwarz PN, Stegmann E, Wohlleben W, Wolański M, Krawiec M, Zakrzewska-Czerwińska J, Méndez C, Botas A, Núñez LE, Morís F, Cortés J, Gross H.

Genome Announc. 2016 Dec 15;4(6). pii: e01391-16. doi: 10.1128/genomeA.01391-16.

9.

Developing a Biocascade Process: Concurrent Ketone Reduction-Nitrile Hydrolysis of 2-Oxocycloalkanecarbonitriles.

Liardo E, Ríos-Lombardía N, Morís F, González-Sabín J, Rebolledo F.

Org Lett. 2016 Jul 15;18(14):3366-9. doi: 10.1021/acs.orglett.6b01510. Epub 2016 Jun 30.

PMID:
27357900
10.

Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations.

Martinez-Cruzado L, Tornin J, Santos L, Rodriguez A, García-Castro J, Morís F, Rodriguez R.

Sci Rep. 2016 Jun 13;6:27878. doi: 10.1038/srep27878.

11.

From a Sequential to a Concurrent Reaction in Aqueous Medium: Ruthenium-Catalyzed Allylic Alcohol Isomerization and Asymmetric Bioreduction.

Ríos-Lombardía N, Vidal C, Liardo E, Morís F, García-Álvarez J, González-Sabín J.

Angew Chem Int Ed Engl. 2016 Jul 18;55(30):8691-5. doi: 10.1002/anie.201601840. Epub 2016 Jun 3.

PMID:
27258838
12.

Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.

Tornin J, Martinez-Cruzado L, Santos L, Rodriguez A, Núñez LE, Oro P, Hermosilla MA, Allonca E, Fernández-García MT, Astudillo A, Suarez C, Morís F, Rodriguez R.

Oncotarget. 2016 May 24;7(21):30935-50. doi: 10.18632/oncotarget.8817.

13.

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.

Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ.

Clin Cancer Res. 2016 Aug 15;22(16):4105-18. doi: 10.1158/1078-0432.CCR-15-2624. Epub 2016 Mar 15.

14.

EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.

Civenni G, Longoni N, Costales P, Dallavalle C, García Inclán C, Albino D, Nuñez LE, Morís F, Carbone GM, Catapano CV.

Mol Cancer Ther. 2016 May;15(5):806-18. doi: 10.1158/1535-7163.MCT-15-0791. Epub 2016 Jan 29.

15.

Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-Mithramycin SK (EC-8042).

Fernández-Guizán A, López-Soto A, Acebes-Huerta A, Huergo-Zapico L, Villa-Álvarez M, Núñez LE, Morís F, Gonzalez S.

PLoS One. 2015 Nov 4;10(11):e0140786. doi: 10.1371/journal.pone.0140786. eCollection 2015.

16.

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.

Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC.

Oncotarget. 2015 Oct 20;6(32):32856-67. doi: 10.18632/oncotarget.5942.

17.

Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.

Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sanchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A.

Oncotarget. 2015 Oct 13;6(31):31272-83. doi: 10.18632/oncotarget.5211.

18.

Expanding the Chemical Diversity of the Antitumoral Compound Mithramycin by Combinatorial Biosynthesis and Biocatalysis: The Quest for Mithralogs with Improved Therapeutic Window.

Méndez C, González-Sabín J, Morís F, Salas JA.

Planta Med. 2015 Oct;81(15):1326-38. doi: 10.1055/s-0035-1557876. Epub 2015 Sep 21. Review.

PMID:
26393942
19.

Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer.

Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A.

Oncotarget. 2015 Sep 29;6(29):27923-37. doi: 10.18632/oncotarget.4736.

20.

Cytotoxic effects of mithramycin DIG-MSK can depend on the rise of autophagy.

Vizcaíno C, Rodríguez-Sánchez MA, Núñez LE, Morís F, Portugal J.

Toxicol In Vitro. 2015 Oct;29(7):1537-44. doi: 10.1016/j.tiv.2015.06.008. Epub 2015 Jun 13.

PMID:
26079942
21.

Chemoenzymatic one-pot synthesis in an aqueous medium: combination of metal-catalysed allylic alcohol isomerisation-asymmetric bioamination.

Ríos-Lombardía N, Vidal C, Cocina M, Morís F, García-Álvarez J, González-Sabín J.

Chem Commun (Camb). 2015 Jul 11;51(54):10937-40. doi: 10.1039/c5cc03298a.

PMID:
26062926
22.

Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue.

Vizcaíno C, Núñez LE, Morís F, Portugal J.

PLoS One. 2014 Aug 11;9(8):e104687. doi: 10.1371/journal.pone.0104687. eCollection 2014.

23.

The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription.

Fernández-Guizán A, Mansilla S, Barceló F, Vizcaíno C, Núñez LE, Morís F, González S, Portugal J.

Chem Biol Interact. 2014 Aug 5;219:123-32. doi: 10.1016/j.cbi.2014.05.019. Epub 2014 Jun 4.

24.

Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers.

Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A, Moris F, Rodrigo L, Mira A, Collado MC.

J Gastroenterol. 2015 Feb;50(2):167-79. doi: 10.1007/s00535-014-0963-x. Epub 2014 May 9.

PMID:
24811328
25.

Generation by mutasynthesis of potential neuroprotectant derivatives of the bipyridyl collismycin A.

Sialer C, García I, González-Sabín J, Braña AF, Méndez C, Morís F, Salas JA.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5707-9. doi: 10.1016/j.bmcl.2013.08.017. Epub 2013 Aug 12.

PMID:
23993774
26.

Engineering the biosynthesis of the polyketide-nonribosomal peptide collismycin A for generation of analogs with neuroprotective activity.

Garcia I, Vior NM, González-Sabín J, Braña AF, Rohr J, Moris F, Méndez C, Salas JA.

Chem Biol. 2013 Aug 22;20(8):1022-32. doi: 10.1016/j.chembiol.2013.06.014. Epub 2013 Aug 1.

27.

Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes.

Vizcaíno C, Mansilla S, Núñez LE, Méndez C, Salas JA, Morís F, Portugal J.

Biochem Pharmacol. 2012 Nov 1;84(9):1133-42. doi: 10.1016/j.bcp.2012.08.003. Epub 2012 Aug 14.

PMID:
22981341
28.

Lipase-catalyzed preparation of chromomycin A₃ analogues and biological evaluation for anticancer activity.

González-Sabín J, Núñez LE, Menéndez N, Braña AF, Méndez C, Salas JA, Gotor V, Morís F.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4310-3. doi: 10.1016/j.bmcl.2012.05.015. Epub 2012 May 11.

PMID:
22647722
29.

A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis.

Núñez LE, Nybo SE, González-Sabín J, Pérez M, Menéndez N, Braña AF, Shaaban KA, He M, Morís F, Salas JA, Rohr J, Méndez C.

J Med Chem. 2012 Jun 28;55(12):5813-25. doi: 10.1021/jm300234t. Epub 2012 Jun 7.

30.

Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.

Malek A, Núñez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, Morís F, Catapano CV.

PLoS One. 2012;7(4):e35130. doi: 10.1371/journal.pone.0035130. Epub 2012 Apr 19.

31.

Elucidating the biosynthetic pathway for the polyketide-nonribosomal peptide collismycin A: mechanism for formation of the 2,2'-bipyridyl ring.

Garcia I, Vior NM, Braña AF, González-Sabin J, Rohr J, Moris F, Méndez C, Salas JA.

Chem Biol. 2012 Mar 23;19(3):399-413. doi: 10.1016/j.chembiol.2012.01.014.

32.

The NFκB pathway: a therapeutic target in glioblastoma.

Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL.

Oncotarget. 2011 Aug;2(8):646-53. Review.

33.

The chromomycin CmmA acetyltransferase: a membrane-bound enzyme as a tool for increasing structural diversity of the antitumour mithramycin.

García B, González-Sabín J, Menéndez N, Braña AF, Núñez LE, Morís F, Salas JA, Méndez C.

Microb Biotechnol. 2011 Mar;4(2):226-38. doi: 10.1111/j.1751-7915.2010.00229.x. Epub 2010 Nov 18.

34.

Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles.

Sánchez C, Salas AP, Braña AF, Palomino M, Pineda-Lucena A, Carbajo RJ, Méndez C, Moris F, Salas JA.

Chem Commun (Camb). 2009 Jul 21;(27):4118-20. doi: 10.1039/b905068j. Epub 2009 May 27.

PMID:
19568652

Supplemental Content

Support Center